Analyst consensus rating
Enliven Therapeutics Analyst Rating: none
Direct answer
Enliven Therapeutics's consensus rating is none.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $73.90.
Forecast evidence checked September 7, 2026.
Get free Enliven Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $59.32
- Average price target
- $73.90
- High price target
- $82.00
- Low price target
- $64.00
- Low target gap
- +7.9%
- Target upside
- +24.6%
- High target gap
- +38.2%
- Target range width
- 30.3%
- Consensus rating
- none
- Analysts
- 10
- Evidence date
- September 7, 2026
- Valid through
- September 14, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Enliven Therapeutics?
Enliven Therapeutics has a verified none consensus. The same dataset has an average price target of $73.90.
How far are Enliven Therapeutics's low and high targets from the recorded price?
The low target implies +7.9%, while the high target implies +38.2%.
How many analysts are included in Enliven Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is Enliven Therapeutics's target upside or downside calculated?
The average target of $73.90 is divided by the recorded price of $59.32, then one is subtracted to produce +24.6%. This does not guarantee a future return.
When was Enliven Therapeutics's analyst forecast verified?
The data was verified on 2026-09-07. The dataset is valid through 2026-09-14.